#1 Clinical Trials Search in Europe

Study on the Effectiveness of Ambroxol and Clenbuterol in Children and Adults with Gaucher Disease Type 3

1 1 1

What is this study about?

This clinical trial is focused on studying the effectiveness of a medication called ambroxol in treating individuals with Gaucher disease type 3. Gaucher disease is a rare genetic disorder where fatty substances accumulate in certain organs and tissues, leading to various health issues. The study aims to understand how ambroxol affects certain substances in the body, particularly in the cerebrospinal fluid, which is the liquid surrounding the brain and spinal cord.

Participants in the study will receive ambroxol, which is known to help with respiratory conditions, but in this trial, it is being tested for its potential benefits in Gaucher disease type 3. The study will also involve a comparison with a placebo to evaluate the true effects of ambroxol. The trial will monitor changes in specific markers in the body, such as Lyso-GL1, which are related to the disease, as well as assess improvements in quality of life and other health outcomes.

The study will take place over a period of time, allowing researchers to gather data on how ambroxol impacts the disease and its symptoms. Participants will be regularly assessed to track any changes in their condition and overall well-being. This research is important for potentially finding new ways to manage Gaucher disease type 3 and improve the lives of those affected by it.

1 joining the study

The study focuses on the effectiveness of ambroxol in individuals with Gaucher disease type 3.

Participants must have a documented deficiency of GCase activity and a GBA genotype that fits GD3.

Participants must be receiving enzyme replacement therapy (ERT) at the time of enrollment.

2 medication administration

Participants will receive ambroxol orally. The specific dosage and frequency will be determined by the study protocol.

The main objective is to observe the effect of ambroxol on cerebrospinal fluid (CSF) Lyso-GL1 levels.

3 monitoring and assessments

Regular assessments will be conducted to monitor changes in CSF and plasma levels of various substances, including Lyso-GL1, GL-1, chitotriosidase, and Lyso-GM3.

The study will also evaluate the effect of ambroxol on functional and developmental outcomes, quality of life, ataxia, and neuropsychological outcomes.

If applicable, the effect on seizure control will be assessed using specific scales and a seizure log book.

4 study duration

The estimated end date for the study is September 1, 2027.

Participants will be involved in the study from the recruitment start date, which is estimated to begin on September 16, 2024.

Who Can Join the Study?

  • The patient or the parent(s) / legal guardian(s) must provide written informed consent before the start of the study. This means they agree to participate after understanding the study details.
  • Both male and female patients with a documented deficiency of GCase activity and GBA genotype fitting GD3. This means they have specific genetic markers related to Gaucher disease type 3.
  • Male and female patients of all ages can participate.
  • The patient must be able to travel to the study site.
  • Patients must be receiving ERT (Enzyme Replacement Therapy) with treatment ongoing at the time of enrollment. This means they are already undergoing a specific treatment for their condition.

Who Cannot Join the Study?

  • Patients who do not have Gaucher disease type 3. This is a specific type of a genetic disorder.
  • Patients who are not within the specified age range for the study.
  • Patients who are not part of the specified clinical trial group.
  • Patients who are not able to provide informed consent or are considered part of a vulnerable population.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Adztfkwah Uau Amsterdam The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Recruiting
16.09.2024

Trial locations

Investigated drugs:

Ambroxol is a medication being studied for its potential effectiveness in treating Gaucher disease type 3. In this clinical trial, researchers are investigating how ambroxol affects a specific substance in the cerebrospinal fluid of patients with this condition. Gaucher disease type 3 is a rare genetic disorder, and the trial aims to see if ambroxol can help manage or improve symptoms related to this disease.

Gaucher Disease Type 3 – This is a rare genetic disorder that affects the body’s ability to break down a certain type of fat, leading to its accumulation in various organs. It is characterized by neurological symptoms, including eye movement disorders, seizures, and cognitive decline, alongside the more common symptoms of Gaucher disease such as enlarged liver and spleen, bone pain, and fatigue. The progression of neurological symptoms can vary, with some individuals experiencing a slow progression while others may have more rapid changes. The disease is caused by a deficiency in the enzyme glucocerebrosidase, which leads to the buildup of glucocerebroside in cells. This accumulation primarily affects the brain and other parts of the nervous system, as well as the spleen, liver, and bone marrow. The severity and range of symptoms can differ significantly among individuals with this condition.

Trial ID:
2024-514012-28-00
Protocol code:
NL76160.018.21
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark Italy The Netherlands Spain

  • Study on Metformin and Colchicine for Patients with Long COVID Symptoms

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands